Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Exelixis, Inc.    EXEL

EXELIXIS, INC.

(EXEL)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
05/22/2020 05/26/2020 05/27/2020 05/28/2020 05/29/2020 Date
24.62(c) 24.32(c) 24.4(c) 24.33(c) 24.71(c) Last
2 112 938 5 193 064 2 617 401 1 976 413 2 836 526 Volume
-0.12% -1.22% +0.33% -0.29% +1.56% Change
More quotes
Financials (USD)
Sales 2020 902 M - -
Net income 2020 140 M - -
Net cash position 2020 1 330 M - -
P/E ratio 2020 55,8x
Yield 2020 -
Sales 2021 1 179 M - -
Net income 2021 279 M - -
Net cash position 2021 1 624 M - -
P/E ratio 2021 27,6x
Yield 2021 -
Capitalization 7 578 M 7 578 M -
EV / Sales 2020 6,92x
EV / Sales 2021 5,05x
Nbr of Employees 617
Free-Float 96,9%
More Financials
Company
Exelixis, Inc. is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company's cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors. The Company's CABOMETYX tablets are approved for previously treated advanced kidney cancer and COMETRIQ... 
More about the company
Surperformance© ratings of Exelixis, Inc.
Trading Rating : Investor Rating :
More Ratings
Latest news on EXELIXIS, INC.
05/22EXELIXIS, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
05/13EXELIXIS : Announces Results From COSMIC-021 Trial of Cabozantinib in Combinatio..
BU
05/06EXELIXIS : to Webcast Fireside Chats as Part of Virtual Investor Conferences in ..
BU
05/05EXELIXIS : 1Q Earnings Snapshot
AQ
05/05EXELIXIS : Management's Discussion and Analysis of Financial Condition and Resul..
AQ
05/05EXELIXIS, INC. : Results of Operations and Financial Condition, Financial Statem..
AQ
05/05EXELIXIS : Announces First Quarter 2020 Financial Results and Provides Corporate..
BU
04/21EXELIXIS : to Release First Quarter 2020 Financial Results on Tuesday, May 5, 20..
BU
04/21IPSEN : announces positive topline results from pivotal Phase III CheckMate -9ER..
AQ
04/21Bristol Myers Squibb and Exelixis Announce Positive Topline Results from Pivo..
AQ
04/21Ono and Takeda Announce Results from Phase 3 CheckMate -9ER Study for Opdivo ..
AQ
04/20EXELIXIS : Shares Hit 52-Week High on Phase 3 Study Data
DJ
04/20BRISTOL MYERS SQUIBB : Myers, Exelixis Phase 3 Kidney Cancer Study Meets Main En..
DJ
04/08EXELIXIS : to Webcast Virtual Fireside Chat as Part of the Needham Healthcare Co..
BU
03/25EXELIXIS : Announces Partner Takeda Receives Approval in Japan for CABOMETYX® (c..
BU
More news
News in other languages on EXELIXIS, INC.
05/22EXELIXIS, INC. : Change in Directors or Principal Officers (form 8-K)
05/13EXELIXIS : Announces Results From COSMIC-021 Trial of Cabozantinib in Combinatio..
05/06EXELIXIS : to Webcast Fireside Chats as Part of Virtual Investor Conferences in ..
05/05EXELIXIS : 1Q Earnings Snapshot
05/05EXELIXIS : Management's Discussion and Analysis of Financial Condition and Resul..
More news
Chart EXELIXIS, INC.
Duration : Period :
Exelixis, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EXELIXIS, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 16
Average target price 28,90 $
Last Close Price 24,71 $
Spread / Highest target 61,9%
Spread / Average Target 17,0%
Spread / Lowest Target -15,0%
EPS Revisions
Managers
NameTitle
Michael M. Morrissey President, Chief Executive Officer & Director
Stelios B. Papadopoulos Chairman
Christopher J. Senner Chief Financial & Accounting Officer, Executive VP
Gisela M. Schwab Chief Medical Officer & President-Medical Affairs
Peter Lamb Chief Scientific Officer & EVP-Scientific Strategy
Sector and Competitors
1st jan.Capitalization (M$)
EXELIXIS, INC.40.24%7 578
GILEAD SCIENCES19.78%97 628
VERTEX PHARMACEUTICALS31.52%74 661
REGENERON PHARMACEUTICALS63.21%68 243
WUXI APPTEC CO., LTD.15.61%33 459
GENMAB A/S39.05%20 072